Prospera Financial Services Inc Purchases 1,763 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Prospera Financial Services increased its Thermo Fisher Scientific stake by 11.6% in the second quarter, adding 1,763 shares to hold 16,946 shares valued at approximately $8.5 million. Institutional investors collectively own 89.23% of the company.
• Analysts maintain a “Moderate Buy” consensus on TMO, with 17 Buy, six Hold, and one Strong Buy rating and an average price target of $619.41.
• Thermo Fisher exceeded quarterly expectations with $6.03 in EPS and $11.99 billion in revenue, while revenue grew 10.5% year over year. The company also declared a quarterly dividend of $0.47 per share, representing a 0.3% yield.

Prospera Financial Services Inc boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 11.6% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 16,946 shares of the medical research company's stock after acquiring an additional 1,763 shares during the period. Prospera Financial Services Inc's holdings in Thermo Fisher Scientific were worth $8,499,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its position in shares of Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after purchasing an additional 988 shares during the period. Revolve Wealth Partners LLC boosted its holdings in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after buying an additional 20 shares during the period. Darwin Wealth Management LLC purchased a new position in Thermo Fisher Scientific in the 2nd quarter valued at approximately $170,000. Raymond James Financial Inc. raised its holdings in Thermo Fisher Scientific by 7.4% during the 2nd quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company's stock valued at $315,781,000 after acquiring an additional 53,542 shares during the period. Finally, California State Teachers Retirement System lifted its position in shares of Thermo Fisher Scientific by 0.4% during the second quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company's stock worth $244,099,000 after acquiring an additional 2,262 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. HSBC cut Thermo Fisher Scientific from a "buy" rating to a "hold" rating and reduced their price target for the company from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Robert W. Baird cut their target price on Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating for the company in a research note on Friday, April 24th. Piper Sandler lifted their target price on Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a "neutral" rating in a report on Monday, July 27th. Wells Fargo & Company lowered their price target on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating on the stock in a report on Friday, May 8th. Finally, Royal Bank Of Canada raised their price objective on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a "sector perform" rating in a research report on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $619.41.

Insider Transactions at Thermo Fisher Scientific

In other news, VP Lisa P. Britt sold 5,850 shares of the company's stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $580.00, for a total value of $3,393,000.00. Following the completion of the sale, the vice president owned 14,784 shares of the company's stock, valued at approximately $8,574,720. This represents a 28.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 4,608 shares of the stock in a transaction on Friday, August 7th. The shares were sold at an average price of $586.12, for a total transaction of $2,700,840.96. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 52,053 shares of company stock worth $30,643,589. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Trading Down 1.3%

NYSE TMO opened at $588.17 on Friday. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The stock's 50-day simple moving average is $529.37 and its two-hundred day simple moving average is $509.58. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $643.99. The company has a market capitalization of $217.48 billion, a price-to-earnings ratio of 31.64, a PEG ratio of 2.42 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.71 by $0.32. The firm had revenue of $11.99 billion during the quarter, compared to analysts' expectations of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company's revenue for the quarter was up 10.5% compared to the same quarter last year. During the same period in the prior year, the business earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Research analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.11%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source